Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 20:00 ET | Source: Optigo Biotherapeutics Inc.

Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference

Optigo Bio Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at ARVO 2025
April 01, 2025 10:00 ET | Source: Thought Leadership & Innovation Foundation

Thought Leadership & Innovation Foundation Awareness Month Published on American Hospital Association/Society for Health Care Strategy & Market Development Observance Calendar

Thought Leadership & Innovation Foundation Awareness Month Published on SHSMD Observance Calendar
October 11, 2024 08:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Age-related Macular Degeneration Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™

Delray Beach, FL, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust CAGR of 10.7%. This...
December 04, 2023 14:45 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

RETINALGENIX TECHNOLOGIES INC. APPOINTS DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
December 01, 2023 12:32 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO Virender Ahluwalia will serve as Interim Chief Financial Officer
November 28, 2023 16:01 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board

RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company
November 09, 2023 12:58 ET | Source: RetinalGeniX Technologies, Inc.

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration and Alzheimer’s Syndrome.
August 01, 2023 11:14 ET | Source: Straits Research

Dry Age-Related Macular Degeneration Market Size is projected to reach USD 3.19 billion by 2031, growing at a CAGR of 8.06%: Straits Research

New York, United States, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Age-related macular degeneration (AMD) disease causes the small central retinal macula of the eye to deteriorate. A crucial retina...
June 19, 2023 09:20 ET | Source: Straits Research

Macular Degeneration Treatment Market Size is projected to reach USD 15.16 billion by 2030, growing at a CAGR of 7.06%: Straits Research

New York, United States, June 19, 2023 (GLOBE NEWSWIRE) -- The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision...